← boothcheck

AME vs WAT stock comparison

AMETEK, Inc. vs Waters Corporation, two Scientific Instruments stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

The margin gap is the story, and for once it points at the acquirer rather than the specialist: AMETEK's 26.7% operating margin against Waters' negative 3.7%, a franchise mid-stumble. Waters' positive 11.9% net margin marks the operating loss as carrying one-time freight rather than a broken business, but the pair still prices oddly: 47.4 times Waters' depressed earnings against 35.9 times AMETEK's healthy ones. Returns on equity sit at 14% and 3%. The market is paying a premium multiple for Waters' recovery and a smaller one for AMETEK's consistency, which is a reasonable disagreement about time. Only one of the two arguments needs something to change.

Comparison updated 2026-07-10.

AME vs WAT: the numbers

MetricAMEWAT
Price$237.48$374.11
Market cap$54.6B$30.7B
SectorScientific InstrumentsScientific Instruments
StageMatureGrowth
P/E35.947.4
P/B5.002.01
P/S7.188.09
EV/EBITDA23.554.6
Revenue growth+9.5%+28.6%
Operating margin26.7%-3.7%
Net margin20.1%11.9%
Return on equity14.0%3.0%
Return on assets9.4%1.8%
Return on invested capital12.2%2.4%
FCF yield3.1%1.1%
Dividend yield0.2%
Debt / equity0.200.32
Current ratio1.141.79
Altman Z (solvency)7.682.82
Piotroski F (quality)7 / 93 / 9
Full AME report → Full WAT report →
Get boothcheck's read on AME and WAT, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.